New York, March 3, 2026, 09:45 EST — Regular session
- Arcus Biosciences shares eased in early Tuesday trade after a sharp Monday jump
- Leerink lifted its target to $49; traders are watching whether the move sticks
- Next on the calendar: a March 9 fireside chat at the Leerink Global Healthcare Conference
Arcus Biosciences Inc shares were down about 3.5% at $23.10 in early trading on Tuesday, giving back some of the prior session’s surge. The stock was off about 0.9% in premarket trading. 1
The pullback matters now because RCUS has turned into a “one-program” trade again, with the market marking up or trimming the stock on any fresh read of its kidney-cancer story. In that kind of tape, a single note can move price — and then just as quickly stop working.
It also lands in a busy stretch for healthcare conferences and biotech positioning, when investors tend to demand tighter timelines and cleaner funding plans. Small caps that jump fast can get tested the next morning.
Arcus ended Monday at $23.94, up $3.57 from Friday’s $20.37 close — a gain of about 17.5% on the day. 2
Leerink Partners raised its price target on Arcus to $49 from $36 and kept an “outperform” rating, according to a report highlighted on Monday. A price target is simply an analyst’s estimate of where a stock could trade over the next 12 months. 3
Arcus said on Feb. 25 that updated data for casdatifan in late-line kidney cancer showed a median progression-free survival of 15.1 months, and it ended 2025 with about $1.0 billion in cash, cash equivalents and marketable securities. “We are focused on rapidly enrolling PEAK-1,” chief executive Terry Rosen said in that release. 4
In a separate Feb. 23 update, chief medical officer Richard Markus said: “Patients in the 100mg tablet cohort reached 15.1 months of PFS, and 45% had a confirmed response.” Progression-free survival measures how long patients live without the cancer getting worse. 5
Casdatifan targets HIF-2α, a pathway already validated in kidney cancer by Merck’s belzutifan (Welireg). The U.S. FDA approved belzutifan in 2023 for certain adults with advanced renal cell carcinoma after prior therapies. 6
A separate pressure point for traders is dilution risk. A recent SEC prospectus shows Arcus set up an at-the-market program of up to $200 million, allowing it to sell shares into the market over time at prevailing prices. 7
But biotech rallies can fade quickly when the next dataset disappoints, enrollment drags, or the market turns against risk. If investors start to price in equity sales alongside clinical uncertainty, momentum trades can flip.
Investors will get another checkpoint on March 9, when Arcus is scheduled to appear in a fireside chat at the Leerink Global Healthcare Conference at 11:20 a.m. ET. Traders will listen for any shift in trial timing, enrollment language or funding tone. 8
